Platinum-Resistant Ovarian Carcinoma — Trials

Platinum-Resistant Ovarian Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

109 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 56
Recruiting: 29
Ph III recruiting: 3
Growth YoY: —
Industry share: 48%
Top sponsor: National Cancer Institute (NCI)
Termination share: 52.3%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (24)

clinicaltrialsPublishedShowing 1–10 of 10 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05979298	Efficacy of Plasmid Elenagen in Combination With Gemcitabine in Patients With Platinum-resistant Ovarian Cancer	completed	Phase 2	40	CureLab OncologyINDUSTRY	1	Aug 24, 2026	clinicaltrials
NCT03026062	Durvalumab and Tremelimumab in Treating Participants With Recurrent or Refractory Ovarian, Primary Peritoneal, or Fallopian Tube Cancer	completed	Phase 2	100	M.D. Anderson Cancer CenterOTHER	1	Aug 5, 2026	clinicaltrials